Hiltonol

Generic Name: Hiltonol

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 59789-29-6

Unique Ingredient Identifier: 7KYP9TKT70

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: Poly-ICLC
Biological: Peptides

First Posted Date: 2013-10-28

Last Posted Date: 2024-11-05

Lead Sponsor: Patrick Ott, MD, PhD

Target Recruit Count: 15

Registration Number: NCT01970358

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Biological: WT1 126-134 peptide vaccine
Biological: basiliximab
Drug: Montanide ISA 51 VG
Drug: poly ICLC
Other: laboratory biomarker analysis

First Posted Date: 2013-04-29

Last Posted Date: 2018-03-09

Lead Sponsor: University of Chicago

Target Recruit Count: 7

Registration Number: NCT01842139

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Alkylating Agent-Related Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Refractory Anemia With Excess Blasts in Transformation

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Drug: Poly ICLC

First Posted Date: 2013-04-17

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT01834248

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: Poly ICLC
Procedure: leukapheresis

First Posted Date: 2013-02-04

Last Posted Date: 2015-10-02

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 1

Registration Number: NCT01783431

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Poly ICLC

First Posted Date: 2011-02-18

Last Posted Date: 2012-08-13

Lead Sponsor: Rockefeller University

Target Recruit Count: 6

Registration Number: NCT01299662

Locations: 🇺🇸
The Rockefeller University, New York, New York, United States

A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas

Phase 2

Completed

Conditions: Brain Tumors

Interventions: Drug: Poly ICLC

First Posted Date: 2010-08-25

Last Posted Date: 2023-06-12

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 23

Registration Number: NCT01188096

Locations: 🇺🇸
RADY Children's Hospital, San Diego, California, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas

Phase 1

Completed

Conditions: Newly Diagnosed Pediatric Pontine Glioma
Newly Diagnosed Pediatric High Grade Glioma
Recurrent Pediatric Low Grade Glioma
Recurrent Pediatric High Grade Glioma

Interventions: Biological: HLA-A2 restricted glioma antigen peptides vaccine
Biological: Poly-ICLC

First Posted Date: 2010-05-25

Last Posted Date: 2024-12-06

Lead Sponsor: James Felker

Target Recruit Count: 60

Registration Number: NCT01130077

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

DCVax Plus Poly ICLC in Healthy Volunteers

Phase 1

Completed

Conditions: HIV-1 Infection
HIV Infection
Healthy Volunteers

Interventions: Drug: DCVax-001
Drug: Placebo
Drug: Poly-ICLC

First Posted Date: 2010-05-20

Last Posted Date: 2014-05-08

Lead Sponsor: Rockefeller University

Target Recruit Count: 43

Registration Number: NCT01127464

Locations: 🇺🇸
Rockefeller University, New York, New York, United States

Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma

Phase 1

Terminated

Conditions: B Cell Lymphoma
T Cell Lymphoma

Interventions: Drug: Poly-ICLC

First Posted Date: 2009-04-14

Last Posted Date: 2011-07-20

Lead Sponsor: Nevada Cancer Institute

Target Recruit Count: 3

Registration Number: NCT00880867

Locations: 🇺🇸
Nevada Cancer Institute, Las Vegas, Nevada, United States

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

Phase 1

Completed

Conditions: Influenza
Severe Acute Respiratory Distress Syndrome
Smallpox
Ebola
Unknown Respiratory Viruses

First Posted Date: 2008-03-28

Last Posted Date: 2018-07-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT00646152

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy